Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study

被引：14
|
作者：
Botzenhardt, Sebastian [1 ]
Felisi, Mariagrazia [2 ]
Bonifazi, Donato [2 ]
Del Vecchio, Giovanni C. [3 ]
Putti, Maria C. [4 ]
Kattamis, Antonis [5 ]
Ceci, Adriana [2 ,6 ]
Wong, Ian C. K. [7 ,8 ]
Neubert, Antje [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Fac Med, Dept Paediat & Adolescent Med, Erlangen, Germany
[2] Consorzio Valutazioni Biol & Farmacol, Pavia, Italy
[3] Policlin Bari, Azienda Osped Univ Consorziale, Bari, Italy
[4] Azienda Osped Padova, Clin Oncoemat Pediat, Padua, Italy
[5] Univ Athens, Dept Pediat 1, Athens, Greece
[6] Gianni Benzi Pharmacol Res Fdn, Bari, Italy
[7] UCL, Sch Pharm, Res Dept Practice & Policy, Ctr Med Optimisat Res & Educ, London, England
[8] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Ctr Safe Medicat Practice & Res, Hong Kong, Hong Kong, Peoples R China
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 01期
关键词：
ORAL IRON CHELATOR; TRANSFUSION-DEPENDENT THALASSEMIA; THERAPY; EFFICACY; OVERLOAD; TRIAL; AGRANULOCYTOSIS; DEFEROXAMINE;
D O I：
10.3324/haematol.2017.176065
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope((R)) in children requiring growth hormone treatment
    Pfaeffle, Roland
    Schwab, Karl Otfried
    Marginean, Otilia
    Walczak, Mieczyslaw
    Szalecki, Mieczyslaw
    Schuck, Ellen
    Zabransky, Markus
    Zucchini, Stefano
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2013, 4 (01) : 3 - 11
  • [42] DURABILITY OF TREATMENT EFFECT WITH LONG-TERM MARALIXIBAT IN CHILDREN WITH ALAGILLE SYNDROME: 4-YEAR SAFETY AND EFFICACY RESULTS FROM THE ICONIC STUDY
    Gonzales, Emmanuel M.
    Sturm, Ekkehard
    Stormon, Michael
    Sokal, Etienne M.
    Hardikar, Winita
    Lacaille, Florence
    Gliwicz-Miedzinska, Dorota
    Hierro, Loreto
    Jaecklin, Thomas
    Vig, Pamela
    Desai, Nirav K.
    Dorenbaum, Alejandro
    Kennedy, Ciara
    Baker, Alastair J.
    Jacquemin, Emmanuel
    HEPATOLOGY, 2019, 70 (06) : 1479A - 1479A
  • [43] Long-term survival and safety from a multi-center, open-label, pivotal phase 2 study of iobenguane I 131 in patients (Pts) with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL).
    Noto, Richard B.
    Jimenez, Camilo
    Chin, Bennett B.
    Dillon, Joseph S.
    Solnes, Lilja
    DiPippo, Vincent A.
    Mahmood, Syed
    Stambler, Nancy
    Lin, Tess
    Jensen, Jessica Donato
    Wong, Vivien
    Pryma, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] THE FIRST PROCEDURELESS GASTRIC BALLOON FOR WEIGHT LOSS: FINAL RESULTS FROM A MULTI-CENTER, PROSPECTIVE STUDY EVALUATING SAFETY, EFFICACY, PARTICIPANT PREFERENCE, AND LONG TERM FOLLOW-UP
    Raftopoulos, I
    Giannakou, A.
    Ioannis, K.
    Bojkova, M.
    Kupka, T.
    Buzga, M.
    Stecco, K.
    Levy, S.
    Gaur, S.
    Chuttani, R.
    Machytka, E.
    OBESITY SURGERY, 2016, 26 : S141 - S142
  • [45] Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
    Sandborn, W. J.
    Lee, S. D.
    Randall, C.
    Gutierrez, A.
    Schwartz, D. A.
    Ambarkhane, S.
    Kayhan, C.
    Pierre-Louis, B.
    Schreiber, S.
    Lichtenstein, G. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (08) : 903 - 916
  • [46] Safety of Valtoco® (Diazepam Nasal Spray) in Children and Adolescents With Epilepsy: Final Subgroup Results From a Phase 3, Long-Term Open-Label, Repeat-Dose Safety Study
    Tarquinio, D.
    Dlugos, D.
    Wheless, J.
    Desai, J.
    Boro, A.
    Carrazana, E.
    Rabinowicz, A.
    ANNALS OF NEUROLOGY, 2021, 90 : S128 - S128
  • [47] Long-term safety and frequency of repeat zuranolone treatment in patients with major depressive disorder rolling over from the randomised CORAL Study into the open-label SHORELINE Study
    Mattingly, G. W.
    Mathew, S. J.
    Parikh, S. V.
    Aaronson, S. T.
    Baune, B. T.
    Czysz, A.
    Nandy, I.
    Ona, V.
    Brown, C.
    Kyaga, S.
    Forrestal, F.
    Levin, S.
    Doherty, J.
    Mattingly, G.
    EUROPEAN PSYCHIATRY, 2024, 67 : S327 - S328
  • [48] Multi-Center Study to Assess the Safety of a Selective Cytopheretic Device (SCD) for Treatment of Immunomodulatory Dysregulation due to AKI in Children ≥10 and ≤20 kg: Report From the First 4 Patients
    Krallman, Kelli A.
    French, Xavier
    Humes, H. David
    Askenazi, David J.
    Yessayan, Lenar T.
    Collins, Michaela
    Potts, Jessica
    Goldstein, Stuart
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 59 - 59
  • [49] Sustained Efficacy With Long-Term Treatment With AXS-05: Results From the COMET Phase 3 Trial, a Long-Term, Open-Label Study Evaluating the Efficacy and Safety of AXS-05 for the Treatment of MDD
    O'Gorman, Cedric
    Jones, Amanda
    Tabuteau, Herriot
    ANNALS OF CLINICAL PSYCHIATRY, 2021, 33 (03) : 16 - 16
  • [50] VEDOLIZUMAB TREATMENT PERSISTENCE UP TO 3 YEARS: POST HOC ANALYSIS IN VEDOLIZUMAB-NAIVE PATIENTS FROM THE GEMINI LONG-TERM SAFETY STUDY
    Loftus, Edward V.
    Vermeire, Severine
    Khalid, Javaria M.
    Tudor, David
    Akbari, Mona
    Demuth, Dirk
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2018, 154 (06) : S387 - S387
12345